Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s travel plans, or lack thereof

Executive Summary

GlaxoSmithKline responds to an article in 1"The Pink Sheet" (April 3, 2006, p. 8) discussing international mergers. "The article quotes comments made by Clifford Kalb, VP of Life Sciences at Wood Mackenzie, speculating on future mergers expected in the pharmaceutical industry," GSK notes. "Among those comments, the article references Mr. Kalb as saying that GlaxoSmithKline's CEO 'recently visited the offices of New Jersey Governor Jon Corzine seeking a tax break to relocate the firm's headquarters.' Mr. Kalb's speculation is completely wrong. The company's CEO has not met with Governor Corzine, and GlaxoSmithKline has no intention of moving its headquarters from the UK to the U.S.," GSK says...

You may also be interested in...



Sanofi-Aventis May Be First In Wave Of National Pharma; Will Swiss Follow?

Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb

Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel